Over 2100 Total Lots Up For Auction at Four Locations - NY 10/25, OK 10/27, TX 10/28, CA 10/29

GenesisCare expands their MR-guided radiotherapy reach with the purchase of multiple MRIdian Systems

Press releases may be edited for formatting or style | June 24, 2021 MRI Rad Oncology
CLEVELAND, June 24, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that GenesisCare has entered into a master purchase agreement for up to 14 MRIdian® MR-Guided Therapy Systems, immediately expanding programs in United Kingdom (UK) and Ft. Myers, Florida. GenesisCare, the largest provider of cancer services globally, has now chosen MRIdian to offer personalized, precise radiation therapy in the U.S. and in three of its UK centers.

"GenesisCare was founded with a mission to provide cancer patients with access to the most comprehensive and advanced treatment possible, no matter their location," said Dan Collins, CEO and founder, GenesisCare. "We work hard to continue to find opportunities to partner with companies who are driving innovation, change, and challenging the status quo of possible treatments. As a team, including ViewRay, The Pancreatic Cancer Research Fund, and the University of Oxford, we've already seen compelling results from the Compassionate Access Programme (in the UK)."

With more than 440 oncology and cardiology centers in total, GenesisCare offers radiotherapy at centers across Europe, Australia, and the United States. Every year more than 400,000 people from around the world receive care through GenesisCare's team of more than 5,500 highly trained healthcare professionals and support staff.

New & Refurbished C-Arm Systems. Call 702.384.0085 Today!

Quest Imaging Solutions provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs

"We're proud to expand our collaboration with GenesisCare. They have demonstrated the value of MRIdian SMART (stereotactic MR-guided adaptive radiotherapy) to patients in the UK at their Oxford site," said Scott Drake, President and CEO of ViewRay. "We now have the opportunity to vastly expand the patient benefits through our partnership in the UK, United States, and beyond. This agreement is a milestone in our mission to treat and prove what others can't."

The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable nearby organs-at-risk and allows the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on implanted markers. By providing real-time continuous tracking of the target and surrounding healthy tissues, MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins. This allows for delivery of the prescribed dose to the target, while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy.

You Must Be Logged In To Post A Comment